NVIDIA launches Jetson Thor robotics computers for physical AI systems
DURHAM, N.C. - Bioventus Inc. (NASDAQ:BVS) reported first quarter results that exceeded analyst expectations on Tuesday.
However, the company’s shares slipped 0.43% in premarket trading following the release.
The medical device company posted adjusted earnings per share of $0.08, beating the consensus estimate of $0.02. Revenue came in at $123.9 million, above the $122.7 million analysts had projected and down 4.3% YoY.
Organic revenue, which excludes the impact of acquisitions and divestitures, grew 5.0% compared to the prior year period. The company said this was driven by positive organic growth across all three of its business segments.
"Our Bioventus team delivered solid results to start the year and we are making substantial progress with executing our strategic plan," said Rob Claypoole, Bioventus President and Chief Executive Officer.
By segment, Pain Treatments revenue rose 3.9% to $58.9 million, Surgical Solutions revenue increased 7.0% to $45.2 million, while Restorative Therapies revenue fell 35.3% to $19.7 million due to the divestiture of the Advanced Rehabilitation business.
Bioventus reiterated its full-year 2025 guidance, forecasting revenue of $560-$570 million and adjusted earnings per share of $0.64-$0.68.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.